J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as ...

Johnson & Johnson (NYSE:JNJ) is one of the most profitable blue chip stocks to invest in now. On March 11, Citi lifted the ...

Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European ...

Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...

Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...

Johnson & Johnson (JNJ) stock is in focus as the company's Erda-iDRS drug delivery system hits the main goal in a Phase 1 trial for bladder cancer. Read more here.

Johnson & Johnson’s position as a diversified healthcare leader continues to attract attention within equity markets. Through ...

The market’s fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month. Consumer sentiment sits at 56.4 on the University of Michigan index, deep in ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent ...

Food ‌and Drug ‌Administration on Thursday approved ​Johnson & Johnson's treatment for a type of ‌blood cancer, ⁠making it ...

Johnson & Johnson (JNJ), Chevron (CVX), Realty Income (O), Broadcom (AVGO), and Agree Realty (ADC) for income investors.